Q1 Earnings Estimate for OKYO Pharma Issued By HC Wainwright

OKYO Pharma Limited (NASDAQ:OKYO) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of OKYO Pharma in a research note issued to investors on Wednesday, October 16th. HC Wainwright analyst Y. Chen expects that the company will post earnings per share of ($0.09) for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for OKYO Pharma’s current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for OKYO Pharma’s Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.38) EPS.

OKYO Pharma Stock Down 1.9 %

OKYO stock opened at $1.03 on Friday. OKYO Pharma has a one year low of $0.81 and a one year high of $2.12. The firm has a 50-day moving average of $1.04 and a two-hundred day moving average of $1.25.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.